Acadian Asset Management
IOVA icon

Acadian Asset Management’s Iovance Biotherapeutics IOVA Stock Holding History

Acadian Asset Management’s Portfolio IOVA Stock Details IOVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-8,417
Closed -$29K – 2100
2026
Q1 		$29K Buy
+8,417
New +$26.9K ﹤0.01% 1907
2024
Q4 		– Sell
-15,071
Closed -$141K – 1887
2024
Q3 		$141K Buy
+15,071
New +$143K ﹤0.01% 1483
2015
Q3 		– Sell
-1,168
Closed -$11K – 1360
2015
Q2 		$11K Buy
+1,168
New +$13K ﹤0.01% 1159

Other funds holding IOVA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
MFM
MHR Fund Management New York $1.92B AUM 119.57% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return

Acadian Asset Management's IOVA Position: Q2 2026 in Review

Acadian Asset Management sold out of Iovance Biotherapeutics (IOVA) in Q2 2026, closing a stake of 8,417 shares — an estimated $29K sold.

Acadian Asset Management first reported a position in IOVA in Q2 2015 and held it in 3 quarters. The position peaked at $141K in Q3 2024. 292 funds tracked by Wall St. Rank hold IOVA as of Q2 2026.

  • Acadian Asset Management reported no remaining Iovance Biotherapeutics position as of Q2 2026 after selling out during the quarter.
  • Acadian Asset Management sold 8,417 Iovance Biotherapeutics shares in Q2 2026, an estimated $29K.
  • Acadian Asset Management first reported a position in Iovance Biotherapeutics in Q2 2015 and held it in 3 quarters.
  • Acadian Asset Management's Iovance Biotherapeutics position peaked at $141K in Q3 2024.
  • 292 funds tracked by Wall St. Rank held Iovance Biotherapeutics as of Q2 2026.

Based on Acadian Asset Management's 13F filing for Q2 2026, filed 13 Aug 2026.